BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 2, 2009
View Archived Issues
Protalix: $115M Gaucher's Deal with Pfizer is Just the Beginning
Shares of Protalix BioTherapeutics Inc. dipped 13.7 percent on Tuesday after the biotech unveiled a $115 million profit-sharing deal with Pfizer Inc. for Gaucher's disease drug Uplyso (taliglucerase alfa). (BioWorld Today)
Read More
Synagis, Synergy: Trellis Getting $338M In RSV MedImmune Deal
Read More
Forma Moving from Platform to Pipeline with $25M Series B
Read More
NewCo News: Syntiron Dressing Up Turkey Vaccine; Possible Human Use
Read More
Bayer Schering Bites on BiTE Option for Micromet Antibody
Read More
Other News To Note
Read More
Clinic Roundup
Read More